|
1 |
Covovax |
Serum Institute of India Pvt. Ltd. |
SARS-CoV-2 rS Protein (COVID-19) recombinant
spike protein Nanoparticle Vaccine |
0000-00-00 |
2022-02-22 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
|
|
|
|
|
|
2 |
Comirnaty |
Pfizer Manufacturing Belgium NV, Rijksweg 12, 2870 Puurs, Belgium. |
Tozinameran-COVID-19 mRNA vaccine (nucleoside modified) |
2021-06-03 |
2021-06-03 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
|
|
|
|
|
|
3 |
Moderna Covid-19 Vaccine |
Moderna TX Inc. |
mRNA-1273 |
0000-00-00 |
2021-06-29 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
|
|
|
|
|
|
4 |
COVID-19 Vaccine Janssen |
Janssen-Cilag International NV, Belgium |
Ad26.COV2.S
|
0000-00-00 |
2021-06-15 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
|
|
|
|
|
|
5 |
CoronaVac |
Sinovac Life Sciences Co., Ltd. No. 21, Tianfu Street, Daxing Biomedicine Industrial Base of Zhongguancun Science Park, Daxing District, Beijing, P.R |
COVID-19 Vaccine (Vero Cell), Inactivated |
0000-00-00 |
2021-06-06 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
|
|
|
|
|
|
6 |
Zhong Al Ke Wei/ COVILO. |
Beijing Institute of Biological Products Co, Ltd. Room 205, Second Floor, Building 4, No 9 Boxing 2nd Road, Economic- Technological Development Area, |
Inactivated SARS-CoV-2 virus (19nCoV-CDC-Tan-HB02 strain) |
0000-00-00 |
2021-04-28 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
|
|
|
|
|
|
7 |
Sputnik V |
GENERIUM Joint-Stock company (GENERIUM JSC), located at 273, Zavodskaya street, Volginsky, Petushinsky District, Vladimir Region, 601125 |
rAd26 and rAd5 adenoviral vector vaccine, which have been modified to contain the SARS-CoV-2 spike protein |
0000-00-00 |
2021-04-27 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
|
|
|
|
|
|
8 |
Covishield |
Serum Institute of India Pvt. Ltd. |
ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant) |
0000-00-00 |
2021-01-08 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
|
|
|
|
|
|
9 |
Act-HIB |
Sanofi Pasteur S A, France |
Haemophilus Influenzae Type B Polysaccjarode 10 ug/dose |
1997-10-29 |
2017-10-28 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
|
|
|
|
|
|
10 |
Imovax Polio Injection |
Sanofi Aventis Pasteur SA, France |
Inactivated Poliovirus Type-1 Ph. Eur 40 antigen D unit
Inactivated Poliovirus Type-2 Ph. Eur 8 antigen D Unit
Inactivated Poliovirus Type-3 Ph. Eur 32 antigen D unit
|
2019-05-06 |
2025-01-24 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
|
|
|
|
|
|
11 |
Pentaxim |
Sanofi Pasteur, France |
Diptheria Toxoid 30 IU
Tetanus Toxoid 40 IU
Bordetella Pertusis Antigens Toxoid 25 mcg
Filamentous Haemagglutinin 25 mcg
Inactivated Type 1 Poliomyelitis Virus 40 DU
Inactivated Type 2 Poliomylit |
2006-02-05 |
2021-02-04 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
|
|
|
|
|
|
12 |
Okavax |
The Research Foundation for Microbial Disease of Osaka University,
Japan |
An attenuated live Varicella-zoster Virus 1400 PFU+ Sodium Chloride 1.6mg+Potassium Chloride 0.04mg+Monobasic Potassium Phosphate 0.4mg+ Dibasic Sodium Phosphate hydrate 4.395mg+Sucrose 35mg+Monosodiu |
2009-06-21 |
2014-06-20 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
|
|
|
|
|
|
13 |
TETRAct-HIB |
Sanofi Pasteur S A, France |
Haemophilus Influenza type b polysaccharide conjugated to tetanus Protein 10mcg+Purified diphtheria toxoid 30IU+Purified tetanus toxoid 60IU+Bordetella pertussis 4IU/0.5ml |
2009-06-21 |
2014-06-20 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
|
|
|
|
|
|
14 |
RotaTeq (Rotavirus Vaccine, Live, Oral, Pentavalent) |
Merck Sharp & Dohme Corp., USA |
G1 Reassortant INN ?2.2 x 106 IU/Dose
G2 Reassortant INN ?2.8 x 106 IU/Dose
G3 Reassortant INN ?2.2 x 106 IU/Dose
G4 Reassortant INN ?2.0 x 106 IU/Dose
P1 Reassortant INN ?2.3 x 106 IU/Dose
|
2014-04-27 |
2024-04-27 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
|
|
|
|
|
|
15 |
GARDASIL (Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant vaccine) |
Merck Sharp & Dohme Corp., USA |
Type 6L1 protein INN 20 µg
Type 11L1 protein INN 40 µg
Type 16L1 protein INN 40 µg
Type 18L1 protein INN 20 µg
|
2014-04-27 |
2024-04-27 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
|
|
|
|
|
|
16 |
Vaxigrip Tetra Quadvivalent Influenza vaccine |
Sanofi Pasteur S A, France |
-A/Michigan/45/2015 (H1N1) pdm 09-like Strain
(A/Michigan/45/2015, NYMC x-275
-A/Hong Kong/4801/2014 (H3N2)-Like Strain
(A/Hong Kong/4801/2014, NYMC x-263B)
-B/Brishane/60/2008-Like strain
(B/Bri |
2019-05-06 |
2024-05-05 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
|
|
|
|
|
|
17 |
Tetraxim |
Sanofi Pasteur, Parc Industriel d’Incarville 27100 Val de Reuil France, Marketing Authorization Holder (MAH): Sanofi Pasteur, 14 Espace Henry Vallee |
Diphtheria toxoid ? 30 IU
Tetanus Toxoid ? 40 IU
Bordetella pertussis antigens: Toxoid 25?g
Filamentous haemagglutinin 25?g
Inactivated type 1 Poliomyelitis virus 40DU
Inactivated type 2 Poliomy |
2020-10-11 |
2025-10-10 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
|
|
|
|
|
|
18 |
Prevenar 13 |
Pfizer Ireland Pharmaceuticals, Grange Castle, Business Park Clondalkin, Dublin-22, Ireland (also responsible for quality control and primary packagin |
Pneumococcal Polysaccharide serotype Ph. Eur. 1,3,4,5,6A, 6B, 7F,9V,14,18C,19A,19F,23F |
2020-12-10 |
2025-12-09 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
|
|
|
|
|
|
19 |
Prevenar 13 (Vaccine) |
Pfizer Manufacturing Belgium NV, Rijksweg 12, 2870 Puurs, Belgium. |
Pneumococcal polysaccharide serotype (13-valent, adsorbed) |
2020-02-25 |
2025-02-24 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
|
|
|
|
|
|
20 |
Nimenrix |
GlaxoSmithKline Biologicals S.A., Belgium for Pfizer Limited, United Kingdom Batch releasing site: Pfizer manufacturing Belgium NV, Rijksweg 12, B-2 |
Neisseria meningitidis group A polysaccharide 5mcg + Neisseria meningitidis group C polysaccharide 5mcg+ Neisseria meningitidis group W-135 polysaccharide 5mcg+ Neisseria meningitidis group Y polysacc |
2018-11-06 |
2023-11-05 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
|
|
|
|
|
|
21 |
VARIVAX |
Merck Sharp & Dohme Corp, USA |
Oka/Merck Varicella Virus INN 1350 PFU (Plaque-forming units) |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
|
|
|
|
|
|
22 |
Pneumovax 23 (Pneumococcal Vaccine Polyvalent) |
|
Pneumococcal Polysaccharide INN 25mcg/dose of each type |
2014-04-27 |
2024-04-26 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
|
|
|
|
|
|
23 |
MENUMONE-A/C/Y/W-135 |
Sanofi Pasteur Inc., USA
|
Meningococcal Polysacharide of Neisseria Meningitis Gr. A 50µg + Meningococcal Polysacharide of Neisseria Meningitis Gr. B 50µg + Meningococcal Polysacharide of Neisseria Meningitis Gr. C 50µg + Menin |
2013-01-31 |
2018-01-30 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
|
|
|
|
|
|
24 |
MENUMONE-A/C/Y/W-135 |
Sanofi Pasteur Inc., USA
|
Meningococcal Polysacharide of Neisseria Meningitis Gr. A 50µg + Meningococcal Polysacharide of Neisseria Meningitis Gr. B 50µg + Meningococcal Polysacharide of Neisseria Meningitis Gr. C 50µg + Menin |
2013-01-31 |
2018-01-30 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
|
|
|
|
|
|
25 |
Vaxigrip Enfants |
Sanofi Pasteur S A, France |
A/California/7/2009(H1N1)-derived Strain Used NYMC X-179A 7.5 Micrograms HA**+ A/Perth/16/2009 (H3N2)-Like strain used NYMC X-187 Derived from A/Victoria/210/2009 7.5 Micrograms HA**+ B/Brisbane/60/20 |
2012-01-23 |
2017-01-22 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
|
|
|
|
|
|
26 |
Prevenar 13 |
Jhon Wyeth & Brother Ltd. UK and Marketing Authorisation Holder
Wyeth Lederle Vaccine SA Belgium |
Pneumococcal Polysaccharide serotype 1 2.2µg +
Pneumococcal Polysaccharide serotype 3 2.2µg + Pneumococcal Polysaccharide serotype 4 2.2µg + Pneumococcal Polysaccharide serotype 5 2.2µg + Pneumoc |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
|
|
|
|
|
|
27 |
BCG-Medac |
Medac Gesellschaft fur Klinische spezialpraparate Germany |
Bacillus calmette-Guerin strain (seed RIVM derived from Seed 1173-p2) at least 2x108 and not more than 2x109 Viable units |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
|
|
|
|
|
|
28 |
Stamaril |
Sanofi Pasteur, France |
Yellow fever Virus 17 D-204 Strain (Live attenuated) ? 1000 LD50 units |
2019-05-06 |
2024-05-05 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
|
|
|
|
|
|
29 |
Vaxigrip |
Sanofi Pasteur S A, France |
A.Brisbane/59/2007(H1N1) 15mcgHA+ A/Brisbane/10/2007(H3N2) 15mcgHA+ B/Florida/4/2006 15mcgHA/0.5ml in P.F.S |
2019-05-06 |
2024-05-05 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
|
|
|
|
|
|
30 |
Pneumo-23 |
Sanofi Pasteur S A, France |
Purified capsular polysaccharides of Streptococcus pneumoniae 1,2,3,4,5.6B, 7F,8,9N,9V,10A, 11A,12F,14, 15B,17F, 18C, 19A,19F,20,22F,23F, 33F for Each of the 23 serotypes 25mcg/ 0.5ml in P.F.S |
2010-02-16 |
2020-02-15 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
|
|
|
|
|
|
31 |
TETRAct-HIB |
Sanofi Pasteur S A, France |
Haemophilus Influenza type b polysaccharide conjugated to tetanus Protein 10mcg+Purified diphtheria toxoid 30IU+Purified tetanus toxoid 60IU+Bordetella pertussis 4IU/0.5ml |
1997-10-29 |
2017-10-28 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
|
|
|
|
|
|
32 |
Favirab |
Sanofi Aventis Pasteur, France |
F(ab’)2 Fragment of equine antirabes immune globulin/ml 200-400 IU |
2008-02-11 |
2018-01-11 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
|
|
|
|
|
|
33 |
Avaxim 80 IU Pediatric |
Aventis Pasteur S.A., France |
Inactivated Hepatitis A Virus Ph. Eur. 80 antigen units |
2019-05-06 |
2024-06-19 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
|
|
|
|
|
|
34 |
Avaxim, Inactivated Hepatitis A Vaccine |
Sanofi Pasteur S A, France |
Inactivated Hepatitis A Virus |
2004-01-17 |
2019-01-16 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
|
|
|
|
|
|
35 |
Inj. Tetabulin (Tetanus Immunoglobulin Human 250IU) |
Baxter AG, Austria |
Tetanus Antitoxin 250IU |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
|
|
|
|
|
|
36 |
Typhim VI |
Sanofi Pasteur S A, France |
Purified Vi capsular polysaccharide of salmonella Typhi (Ty 2 strain) 0.025 mg/dose |
2019-05-06 |
2022-10-28 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
|
|
|
|
|
|
37 |
Act-HIB |
Sanofi Pasteur S A, France |
Haemophilus Influenzae Type B Polysaccjarode 10 ug/dose |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
|
|
|
|
|
|
38 |
Varilrix Vaccine |
Sanofi Pasteur S A, France |
Live Attenuated Varicella Virus Vaccine OKA Strain |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
|
|
|
|
|
|
39 |
Trimovax Injection |
Sanofi Pasteur S A, France |
Vaccinum Morbillorum Vivum, measles, mumps, rubella |
1997-04-27 |
2017-04-26 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
|
|
|
|
|
|
40 |
Maningococcal Polysaccharide Vaccine A+C |
Pasteur Merieux Serums and Vaccines, France |
Maningococcal Polysaccharide Vaccine A+C |
1996-05-12 |
2016-05-11 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
|
|
|
|
|
|
41 |
Hepavax Gene |
Berna Biotech, Korea
|
Hepatitis B Vaccine |
0000-00-00 |
2013-03-13 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
|
|
|
|
|
|
42 |
Human Antitetanus Immune Globulin Grifols 250 IU Injection |
Instituto Grifols S.A., Spain
|
Human Antitetanus Immune Globulin 250 IU |
0000-00-00 |
2010-05-08 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
|
|
|
|
|
|
43 |
Verorab |
Sanofi Pasteur S A, France |
Rabies Virus |
2019-05-06 |
2026-08-17 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
|
|
|
|
|
|
44 |
Rabipur |
Chiron Behring Vaccine Pvt. Ltd.
|
Rabies Virus 2.5 IU |
0000-00-00 |
2015-09-01 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
0000-00-00 |
|
|
|
|
|
